• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mirati Therapeutics, Inc. - Common Stock (NQ:MRTX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 58.85 (1)
Ask (Size) 59.74 (10)
Prev. Close 58.70
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 51,623,193
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 ↗
December 29, 2023
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga
News headline image
EnerSys To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
December 20, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga

Performance

More News

Read More
News headline image
Analyst Expectations For Mirati Therapeutics's Future ↗
December 20, 2023
Via Benzinga
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
November 29, 2023
Via FinancialNewsMedia
Topics Death
News headline image
What 11 Analyst Ratings Have To Say About Mirati Therapeutics ↗
November 07, 2023
Via Benzinga
News headline image
3 Resilient Stocks with Massive Potential to Boost Your Wealth ↗
November 26, 2023
Via InvestorPlace
News headline image
These Three Biotech Stocks Are Trading At A Discount ↗
November 23, 2023
Via Talk Markets
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
November 17, 2023
Via Benzinga
News headline image
3 Biotech Stocks That Could Boom or Bust by 2025 ↗
November 16, 2023
Via InvestorPlace
News headline image
MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX
November 08, 2023
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
3 No-Brainer Stocks to Buy With $500 Right Now ↗
November 08, 2023
Via The Motley Fool
News headline image
Appian To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
November 07, 2023
Via Benzinga
News headline image
Is MIRATI THERAPEUTICS INC Ready to Break Out of Its Range? ↗
November 06, 2023
Via Chartmill
News headline image
7 Healthcare Stocks That Can Cure a Lackluster Portfolio ↗
October 19, 2023
Via InvestorPlace
News headline image
Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings ↗
October 19, 2023
Via Benzinga
News headline image
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race
October 17, 2023
Via PressReach
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq – CNSL), Mirati Therapeutics, Inc.® (Nasdaq - MRTX), Pioneer Natural Resources (NYSE - PXD), Summit Materials (NYSE
October 16, 2023
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Amgen Stock Surges To 10-Month High, Up 4% On An Unexpected Upgrade ↗
October 11, 2023
Via Investor's Business Daily
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023 ↗
October 10, 2023
Via Benzinga
News headline image
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race
October 10, 2023
Via PressReach
News headline image
MIRATI THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX
October 09, 2023
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
October 09, 2023
Via Benzinga
News headline image
Why Shares of Tango Therapeutics Are Dropping Monday ↗
October 09, 2023
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 9, 2023 ↗
October 09, 2023
Via Benzinga
News headline image
Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
October 09, 2023
Via Benzinga

Frequently Asked Questions

Is Mirati Therapeutics, Inc. - Common Stock publicly traded?
Yes, Mirati Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Mirati Therapeutics, Inc. - Common Stock trade on?
Mirati Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Mirati Therapeutics, Inc. - Common Stock?
The ticker symbol for Mirati Therapeutics, Inc. - Common Stock is MRTX on the Nasdaq Stock Market
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap